Roche. which led AveXis' series C round, returned to participate in a series D that will support a clinical trial for its spinal muscular atrophy treatment.
US-based gene therapy developer AveXis closed a $65m series D round yesterday led by investment firm T. Rowe Price that included Roche Venture Fund, the corporate venturing arm of pharmaceutical company Roche.
The round also featured Boxer Capital, which acts as a subsidiary of investment firm Tavistock Group, Deerfield Management, Venrock, Janus Capital Management, Adage Capital Management, RA Capital Management, QVT Financial, Rock Springs Capital Management, Foresite Capital Management and RTW Investments.
AveXis will use the capital to fund ongoing…
